Home/Pipeline/Asundexian (BAY 2433334)

Asundexian (BAY 2433334)

Stroke Prevention after Acute Non-Cardioembolic Ischemic Stroke

Phase IIIOngoingNCT05686070

Key Facts

Indication
Stroke Prevention after Acute Non-Cardioembolic Ischemic Stroke
Phase
Phase III
Status
Ongoing
Company

About Bayer

Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.

View full company profile